Company: FTII
Filing Date: 2025-02-14
Form Type: S-4
Source: 0001493152-25-006997
Chunk: 570

Company: FutureTech II Acquisition Corp.
Filing Date: 2025-02-14
Form: S-4
Chunk 570
---
 accordance with the Merger Agreement, divided by (b) $10.00.

| F-48 |

longevity biomedical, inc.

notes to the financial statements (unaudited)

The consummation of the Merger Transactions are subject to the satisfaction or waiver of certain customary closing conditions contained in the Merger Agreement, including, among other things, requisite approval by FutureTech II’s shareholders.

Denali Capital Acquisition Corp. Merger Agreement

On January 25, 2023, pursuant to the objectives of the Acquisition Transactions contemplated by the C&E Agreements, Longevity entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Denali Capital Acquisition Corp. (“Denali”), a blank-check special purpose acquisition company, Denali SPAC Holdco, Inc. (“New Pubco”), Denali SPAC Merger Sub, Inc., Longevity Merger Sub, Inc., and Bradford A. Zakes (Longevity CEO), in the capacity as seller representative.

On June 27, 2024, Denali and Longevity mutually agreed to terminate the Merger Agreement.

Contribution and Exchange Agreements

On August 7, 2022, the Company entered into Contribution and Exchange Agreements (the “C&E Agreements”) with Cerevast, a related party, Aegeria Soft Tissue LLC, and Novokera, LLC (individually a “Target Company” and collectively the “Target Companies”) and each of the Target Companies respective shareholders and unitholders. Upon the consummation of the transactions contemplated by the C&E Agreements (the “Acquisition Transactions”), the Target Companies will be acquired by Longevity.

The consummation of the Acquisition Transactions is conditioned upon the satisfaction or waiver of certain closing conditions including the entering into and subsequent closing of an approved business combination agreement with a blank-check special purpose acquisition company.

The parties to the C&E Agreements have made customary representations and warranties and have also agreed to certain customary covenants with respect to, among others, the conduct of the business of each Target Company and Longevity prior to the closing of the Acquisitions Transactions.

First Amendment to the C&E Agreement

On January 25, 2023, the Company entered into amendments to the C&E Agreements with each of the Target Companies and each of the Target Companies’ respective shareholders and unitholders pursuant to which certain provisions of the C&E Agreements were amended to, among other things: modify the aggregate valuation assigned to Longevity